NSCLC (NON-SMALL CELL LUNG CANCER)

This early-stage study tests a new drug called TGI-5, alone or with another drug (nivolumab), in people with advanced solid tumors like colorectal, liver, melanoma, and lung cancer. The main goals are to check safety and find the right dose. About 194 adults will take part. This …

This early-phase study tests a new drug called GV20-0251 in people with advanced solid tumors (like liver, lung, or skin cancer) that have stopped responding to standard therapies. The main goal is to check the drug's safety. About 10 participants will receive one of two dose lev…

This study tests a new drug called YH42946 in people with advanced solid tumors (including lung cancer) that have certain gene changes (HER2 or EGFR). The main goals are to check safety, how the drug moves through the body, and whether it shrinks tumors. About 161 participants wh…

This study is testing a new device called CAROL to see if it is safe for treating small lung tumors (2 cm or less) in people with non-small cell lung cancer. The device is placed near the tumor during a procedure, and doctors will monitor for side effects for one month. Only 7 pe…

This early-phase study tests a new drug called XB010, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and check for any side effects. About 396 adults with…

This study tests a new drug called PC14586 (rezatapopt) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The goal is to see if the drug is safe and shrinks tumors. About 300 adults whose cancer has worsened after prior treatment will take the drug al…

This early-phase study tests a new drug called NXP900 in about 140 adults with advanced solid tumors (like lung, kidney, or mesothelioma) that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors…

This study tests a new oral drug, RMC-6236, against standard chemotherapy (docetaxel) in 420 adults with advanced non-small cell lung cancer that has a specific RAS mutation and has already been treated. The goal is to see if the new drug can delay cancer growth and extend life. …

This study is for people with advanced non-small cell lung cancer whose disease got worse after initial immunotherapy and chemotherapy. It tests a combination of microwave ablation (using heat to destroy tumors) plus two drugs (tislelizumab and docetaxel) to see if it can control…

This early-stage trial tests a new drug called ALTA3263 in adults with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a KRAS mutation. The main goals are to check safety and find the right dose. About 188 people whose cancer has worsened after stand…

This study tests a new drug called OSE-279 that helps the immune system fight cancer by blocking a protein called PD-1. It is for people with advanced solid tumors or lymphomas that have not responded to other treatments. The trial has three parts: first finding the safest dose, …

This study tests whether combining the targeted drug ensartinib with standard chemotherapy before surgery can shrink tumors in people with a specific type of lung cancer (ALK-positive non-small cell lung cancer). About 20 adults with stage II to IIIB disease will receive the drug…

This early-phase study tests a new drug called 177LuBetaBart in people with advanced solid tumors that have stopped responding to standard treatments. The drug is a radioactive antibody designed to seek out and destroy cancer cells. The study will check for safety and side effect…

This study tests a new treatment for people with advanced non-small cell lung cancer that no longer responds to standard immunotherapy. The treatment combines a patient's own immune cells (called WAST cells) with a chemotherapy drug (docetaxel). The goal is to see if this combina…

This study tests a drug called serplulimab in elderly patients (65 and older) with advanced non-small cell lung cancer that has a high level of a protein called PD-L1. The goal is to see if the drug can control the cancer and help patients live longer without the disease getting …

This early-phase study tests a new drug called EPI-326 in about 110 people with advanced lung cancer (with a specific EGFR gene change) or head/neck cancer. The main goal is to check safety and find the best dose. Participants receive the drug and are monitored for side effects a…

This study is for people with stage II to IIIB non-small cell lung cancer who had surgery after initial chemotherapy plus immunotherapy but still had some cancer cells left. The trial uses a blood test to look for tiny bits of cancer DNA (called MRD) to decide if more immunothera…

This early-phase trial tests an experimental drug called IAM1363 in people with advanced cancers that have HER2 alterations. The study aims to find a safe dose and see if the drug can shrink tumors, including those that have spread to the brain. About 383 adults whose cancer has …

This study tests a new treatment called A2B395 for adults with advanced solid tumors (like colorectal, lung, breast, and kidney cancers) that have not responded to standard therapy. The treatment uses specially engineered immune cells designed to kill cancer cells while protectin…

This study tests a new experimental drug (PF-07799544) combined with another drug (PF-07799933) in adults with advanced solid tumors that have a specific gene change called BRAF V600. The goal is to see if the combination is safe and can shrink or control the cancer. Participants…

This study looks at how a single, strong dose of radiation to lung tumors affects patients' daily lives and symptoms. About 190 adults with early-stage lung cancer or a few lung metastases that cannot be surgically removed will fill out quality-of-life questionnaires before treat…

This study collects tumor samples from 2,000 people with various cancers to learn how to predict who will respond to immunotherapy. Participants donate tissue during a routine biopsy. The goal is to understand tumor biology and improve future treatment decisions, not to test a ne…